Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection
JAMA Network Open · 02.07.2025 · 8 (7) · e2517834
DOI: 10.1001/jamanetworkopen.2025.17834 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 02.07.2025. Verfasst von Julie A Keating und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison. Hauptthemen laut MEDLINE: Vancomycin, Clostridium Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS.
Abstract (Originalsprache)
Importance Systemic antibiotic use for patients with a non– Clostridioides difficile infection (CDI) is a major risk factor for recurrent CDI. Increasing use of oral vancomycin for secondary prophylaxis against recurrent CDI in this context has uncertain efficacy.
Objective
To evaluate whether oral vancomycin prophylaxis compared with placebo is effective against recurrent CDI during and 8 weeks after the end of study treatment. Design, Setting, and Participants This phase 2, placebo-controlled, double-blind randomized clinical trial was conducted in 4 large health systems across the upper Midwest US. Adults who had completed treatment for CDI within the past 180 days and were taking a systemic antibiotic for a non-CDI indication were enrolled between May 21, 2018, and March 30, 2023, and followed up for 8 weeks after the end of study treatment.
Intervention
Participants were randomized 1:1 to 125 mg of oral vancomycin or placebo once daily during antibiotic use for a non-CDI plus 5 days following cessation of those antibiotics. Main Outcomes and Measures The primary outcome was recurrent CDI incidence during treatment and the 8-week follow-up period. The secondary outcome was vancomycin-resistant Enterococcus carriage in stool.
Results
Among 81 randomized participants (median age, 59 years [IQR, 50-67 years]), all were included in the primary as-randomized analysis (39 in the vancomycin group; 42 in the placebo group). Sixty patients (74.1%) completed 8-week follow-up and were included in the secondary as–completed treatment analysis (31 in the vancomycin group; 29 in the placebo group). Recurrent CDI occurred in 17 of 39 participants in the oral vancomycin group (43.6%) and 24 of 42 in the placebo group (57.1%; absolute difference in percentage, −13.5% [95% CI, −35.1% to 8.0%]). Adverse events occurred in 27 of 39 participants in the oral vancomycin group (69.2%) and 27 of 42 in the placebo group (64.3%). Vancomycin-resistant Enterococcus carriage was found in 15 of 30 patients in the oral vancomycin group (50.0%) and 6 of 25 in the placebo group (24.0%) ( P = .048) 8 weeks after treatment. Conclusions and Relevance In this randomized clinical trial, the incidence of recurrent CDI was lower (though did not reach significance) in participants taking oral vancomycin compared with those taking placebo. Because the study was underpowered, it was unable to reveal firm conclusions about the efficacy (or lack thereof) of vancomycin prophylaxis with respect to recurrent CDI. Trial Registration ClinicalTrials.gov Identifier: NCT03462459
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison.
- William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin.
- Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison.
- Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee.
- Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Förderung
- AHRQ HHS
Zitieren
APA
Keating, J. A., Xu, T., Graham, M. B., Ramesh, M., Khanna, S., Dixon, J., Kates, A., Haight, K., Zhao, J., Saddler, C., & Safdar, N. (2025). Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection. JAMA Network Open, 8(7), e2517834. https://doi.org/10.1001/jamanetworkopen.2025.17834
Vancouver
Keating JA, Xu T, Graham MB, Ramesh M, Khanna S, Dixon J, et al. Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection. JAMA Network Open. 2025;8(7):e2517834. doi:10.1001/jamanetworkopen.2025.17834
BibTeX
@article{Keating2025,
author = {Keating, Julie A and Xu, Tinghui and Graham, Mary Beth and Ramesh, Mayur and Khanna, Sahil and Dixon, Jonah and Kates, Ashley and Haight, Kendra and Zhao, Jiwei and Saddler, Christopher and Safdar, Nasia},
title = {Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {7},
pages = {e2517834},
doi = {10.1001/jamanetworkopen.2025.17834}
}
EUVIMED